Active Clinical Trials for Prostate Cancer


This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Prostate cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
07/17/2014BM-018/13-838Joshua Meyer A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
01/17/2014IRB13864/13-864Yu-Ning Wong Treatment Preference And Patient Centered Prostate Cancer Care
12/10/2013IRB13846/13-846Elias Obeid Genetic Evaluation Of Men - The GEM Registry
09/02/2014TEMPLES1216/13-901Alvaro Pereira-Rico A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK700 with Androgen Deprivation Therapy + Bicalutamide In Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
09/18/2003IRB03835/03-835Eric Horwitz Prospective Collection Of Characteristics And Outcome Of Patients Treated For Prostate Cancer At Fox Chase Cancer Center
05/15/201515-9018/15-9018Marc Smaldone Pennsylvania Urologic Regional Collaborative
12/01/201515-1015/15-1015Daniel Geynisman Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)
09/23/201515-8005/15-8005Suzanne Miller A Pilot Study to Explore Prostate Patients' Understanding of the Meaning of the Gleason Score
07/28/201515-9022/15-9022Eric Horwitz Short term complications in prostate brachytherapy, active surveillance, and prostatectomy.
01/13/2015C28002/14-054Anthony Olszanski A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination with MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients with Advanced Nonhematologic Malignancies
08/05/2015IRB14832/14-832Michael Hall Advancing Web-based Medical Record Access and Risk Evaluation for Cancer Patients (The AWARE Study)
01/14/200908854/08-854Elias Obeid The role of genetic variants at chromosomal loci 8q and 17q in prostate cancer screening in African American men and men with a family history of prostate cancer
09/04/201515-1001/15-1001Marc Smaldone A Prospective, Multi-Institutional, Randomized, Phase II Trial of Best Systemic Therapy (BST) or Best Systemic Therapy Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Metastatic (M1) Prostate Cancer
01/13/201515-9001/15-9001Mark Hallman Comparative effectiveness of different fractionation schemes for treatment of prostate cancer
02/27/2012IRB11825/11-825Suzanne Miller Randomized Controlled Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS - PRostate Cancer Online Guide & Resources for Electronic Survivorship Service)
11/19/1996IRB96091/96-091Elias Obeid Prostate Cancer Risk Assessment Program
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis For Therapy Choice (MATCH)
11/16/2012IRB12861/12-861Elias Obeid Hereditary Cancer Syndromes In Families of Men with Prostate Cancer In A Genetic Counseling Setting
08/04/201414-036/14-036Nestor Esnaola A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Major Cancer Surgery
04/22/2013CTSUS1216/13-701Yu-Ning Wong A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer